Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Free Cash Flow (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Free Cash Flow for 15 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 45.28% year-over-year to $1.1 million, compared with a TTM value of -$842048.0 through Sep 2025, up 57.74%, and an annual FY2024 reading of -$229632.0, up 93.46% over the prior year.
  • Free Cash Flow was $1.1 million for Q3 2025 at Sanara MedTech, up from $902652.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.0 million in Q3 2024 and bottomed at -$3.7 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$848980.8, with a median of -$1.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 235.03% in 2022, then surged 195.24% in 2024.
  • Year by year, Free Cash Flow stood at -$1.9 million in 2021, then surged by 63.74% to -$698380.0 in 2022, then decreased by 29.27% to -$902808.0 in 2023, then soared by 195.24% to $859875.0 in 2024, then rose by 29.9% to $1.1 million in 2025.
  • Business Quant data shows Free Cash Flow for SMTI at $1.1 million in Q3 2025, $902652.0 in Q2 2025, and -$3.7 million in Q1 2025.